Cholinesterase inhibitor use does not significantly influence the ability of (123)I‐FP‐CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies

Documenti analoghi

• Autopsy validation of (123)I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB
  di: Thomas, Alan J., et al.
  Pubblicazione: (2017)
• 123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies
  di: Matteo Pardini, et al.
  Pubblicazione: (2020-05-01)
• ((123)I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study
  di: Siepel, Françoise J, et al.
  Pubblicazione: (2013)
• (123)I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies
  di: Pardini, Matteo, et al.
  Pubblicazione: (2020)
• The Value of Multimodal Imaging with (123)I-FP-CIT SPECT in Differential Diagnosis of Dementia with Lewy Bodies and Alzheimer’s Disease Dementia
  di: Miyagawa, Toji, et al.
  Pubblicazione: (2020)